Asthma and Immunoallergic Diseases

Description

The Research Group in Asthma and Immunoallergic Diseases was integrated into the i+12 Institute at the time of its creation as an emerging group called the “Pediatrics Asthma” group. It dedicates most of its activity to researching the epidemiology of asthma, mainly being involved in the International Study of Asthma and Allergies in Childhood (ISAAC) (prevalence of asthma, allergic rhinitis and atopic dermatitis).

Considering that most allergic pathologies begin during childhood, progressing and persisting throughout adulthood, the confluence of both former groups, the “Inflammatory/Allergic Diseases” group and the “Pediatrics Asthma” group, into the new “Asthma and Immunoallergic Diseases” group, is a brilliant opportunity to continue developing our current lines of research and to explore new common research lines.

Scientific objectives and lines of work

• The study of new biomarkers of airway inflammation among the adult population.
• The study of new biomarkers of airway inflammation among the pediatric population.
• The conduct of phase II/III clinical trials evaluating the efficacy of novel biological treatments (anti-IL-5, anti-IL-13, etc.) or the efficacy of drugs commercialized with another indication (for example, anti-IgE in non-allergic asthma or usefulness of new anticholinergics available for the treatment of chronic obstructive pulmonary disease (COPD) among the adult population.
• The study of new non-invasive biomarkers and identification of new therapeutic targets in patients with eosinophilic esophagitis, in both the adult and the pediatric population.